Relating to exemption of prescription drug sales; prescribing an effective date.
Summary
SB 707 expands Oregon’s corporate activity tax (CAT) exemption for prescription drug sales. Under current law, amounts received by an eligible pharmacy from the sale of prescription drugs are excluded from commercial activity and therefore not subject to the CAT. The bill broadens the definition of “eligible pharmacy” to include not only pharmacies with nine or fewer locations under common ownership in Oregon, but also critical access pharmacies as defined by the Oregon Health Authority for Oregon Prescription Drug Program purposes. It also continues to exclude pharmacies that primarily serve veterinary customers.
The measure applies to tax years beginning on or after January 1, 2026, and takes effect 91 days after adjournment sine die of the 2025 regular session. In practical terms, the bill would reduce CAT liability for qualifying rural and critical access pharmacies by shielding prescription drug sale receipts from the tax base, potentially improving financial stability for smaller community pharmacies and access-focused providers.
Impact
SB 707 amends ORS 317A.123, the statute governing the CAT exemption for prescription drug sales, by expanding the category of pharmacies whose prescription drug receipts are excluded from commercial activity. The change affects the tax treatment of qualifying independent, small-chain, and critical access pharmacies, while leaving larger pharmacy chains and veterinary-focused pharmacies outside the exemption. The bill does not alter the CAT generally, but narrows the tax base for a specific class of pharmacy receipts beginning with tax years on or after January 1, 2026.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the available materials. Based on the bill text and sponsorship, the measure appears to be framed as a targeted tax relief and access-to-care bill for rural and critical access pharmacies. The overall posture is likely favorable toward preserving pharmacy access in underserved areas, with the main policy rationale being relief for smaller providers facing financial pressure.
Contention
The likely point of contention is the scope of the tax exemption: supporters would view the expansion to critical access pharmacies as necessary to support rural health infrastructure, while opponents may argue it further erodes the CAT tax base and creates a preferential tax treatment for a narrow industry segment. Another possible issue is line-drawing—specifically, which pharmacies qualify as “critical access” under Oregon Health Authority rules and whether the exemption should extend beyond small pharmacies to other providers. No specific objections or named dissenting legislators appear in the provided record.